Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a report issued on Wednesday morning.

Several other brokerages also recently commented on PBH. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Trading Up 0.1 %

Shares of NYSE:PBH opened at $78.72 on Wednesday. The stock has a 50 day moving average of $79.25 and a 200 day moving average of $73.04. The company has a market cap of $3.89 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 12-month low of $57.95 and a 12-month high of $86.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the company posted $1.07 earnings per share. The company’s revenue for the quarter was down .9% compared to the same quarter last year. As a group, equities research analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,810 shares of company stock valued at $3,187,300. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently modified their holdings of the stock. Quest Partners LLC raised its holdings in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC raised its stake in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 106.9% in the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company’s stock worth $63,000 after acquiring an additional 448 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.